Revenue beat expectations while earnings missed, by design: R&D spending rose to chase Medical growth, squeezing that segment's adjusted EBITDA margin to 27.4% from 30.6%. Management reaffirmed full-year revenue and adjusted EBIT guidance even after absorbing the RapidFit and Eyewear divestitures.
Materialise Nv
MTLS at a Glance
- Market cap
- $365.4M
- P/E ratio
- 24.7
- Revenue (TTM)
- $274.2M
- Profit margin
- 4.6%
- EPS (TTM)
- $0.26
- 52-week range
- $5 – $9
- Street target
- $9.79
Headquartered in Technologielaan 15, Leuven Fiscal year ends December NASDAQ: MTLS materialise.com
About Materialise
Materialise NV draws on more than three decades of 3D printing experience to provide software solutions and 3D printing services for additive manufacturing applications. It reports through three segments:
- **Materialise Medical:** medical software and personalized, 3D-printed medical solutions. This is its largest segment by revenue.
- **Materialise Software:** open, secure, end-to-end 3D printing software platforms for industrial users.
- **Materialise Manufacturing:** industrial 3D printing and manufacturing services.
Its solutions support flexible industrial manufacturing and mass personalization across healthcare, automotive, aerospace, art and design, wearables, and consumer goods. The company describes itself as combining the largest group of software developers in the 3D printing industry with one of the world's largest 3D printing facilities. During 2026 it divested its RapidFit and Eyewear activities by transferring those assets to their respective management teams, and it is executing a share buyback program. Updated
Frequently Asked Questions
What does Materialise do?
Materialise NV draws on more than three decades of 3D printing experience to provide software solutions and 3D printing services for additive manufacturing applications. It reports through three segments: - **Materialise Medical:** medical software and personalized, 3D-printed medical solutions.
What is the MTLS stock price target?
The Wall Street consensus 12-month price target for MTLS is $9.79.